Oraya Therapeutics, maker of radiosurgical tools used to treat eye diseases, has brought in $42 million in a third round of funding from Domain Associates, Scale Venture Partners, Essex Woodlands Health Ventures and Synergy Life Partners.

Based in Newark, Calif., the company says it will use its new financing to widen its overseas clinical trials. It hopes to earn international approval and clearance for commercialization. Called the IRay system, its lead treatment can deliver precise doses of radiation to parts of the eye to slow age-related degeneration.

Oraya has raised $22 million to date.